JP2024512590A5 - - Google Patents

Info

Publication number
JP2024512590A5
JP2024512590A5 JP2023558745A JP2023558745A JP2024512590A5 JP 2024512590 A5 JP2024512590 A5 JP 2024512590A5 JP 2023558745 A JP2023558745 A JP 2023558745A JP 2023558745 A JP2023558745 A JP 2023558745A JP 2024512590 A5 JP2024512590 A5 JP 2024512590A5
Authority
JP
Japan
Prior art keywords
adapter
car
cells
adbd
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512590A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021633 external-priority patent/WO2022204340A1/en
Publication of JP2024512590A publication Critical patent/JP2024512590A/ja
Publication of JP2024512590A5 publication Critical patent/JP2024512590A5/ja
Pending legal-status Critical Current

Links

JP2023558745A 2021-03-26 2022-03-24 多機能免疫細胞療法 Pending JP2024512590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166550P 2021-03-26 2021-03-26
US63/166,550 2021-03-26
PCT/US2022/021633 WO2022204340A1 (en) 2021-03-26 2022-03-24 Multifunctional immune cell therapies

Publications (2)

Publication Number Publication Date
JP2024512590A JP2024512590A (ja) 2024-03-19
JP2024512590A5 true JP2024512590A5 (cg-RX-API-DMAC10.html) 2025-03-11

Family

ID=83396077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558745A Pending JP2024512590A (ja) 2021-03-26 2022-03-24 多機能免疫細胞療法

Country Status (11)

Country Link
US (1) US20240307439A1 (cg-RX-API-DMAC10.html)
EP (2) EP4596575A3 (cg-RX-API-DMAC10.html)
JP (1) JP2024512590A (cg-RX-API-DMAC10.html)
KR (1) KR20230162957A (cg-RX-API-DMAC10.html)
CN (1) CN117425484A (cg-RX-API-DMAC10.html)
AU (1) AU2022242842A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023019689A2 (cg-RX-API-DMAC10.html)
CA (1) CA3212948A1 (cg-RX-API-DMAC10.html)
IL (1) IL306096A (cg-RX-API-DMAC10.html)
MX (1) MX2023011110A (cg-RX-API-DMAC10.html)
WO (1) WO2022204340A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
CN118679180A (zh) 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2478294C (en) 2002-03-19 2013-09-03 Plant Research International B.V. Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
AU2018368431B2 (en) * 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
SI3710067T1 (sl) * 2017-11-14 2026-01-30 Arcellx, Inc. Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba

Similar Documents

Publication Publication Date Title
AU2018226526B2 (en) Combination of an anti-CD16A antibody with a cytokine
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
US11034766B2 (en) Anti-B7-H6 antibody, fusion proteins, and methods of using the same
KR102098985B1 (ko) Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포
CN116249548A (zh) 用于治疗多发性骨髓瘤的方法
JP7704748B2 (ja) 逐次抗cd19治療
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
CN113728009A (zh) 双特异性CD123 x CD3双抗体在血液系统恶性肿瘤治疗中的给药方案
US20230227527A1 (en) Tcr-t cell therapy targeting epstein-barr virus
JP2024513054A5 (cg-RX-API-DMAC10.html)
JP2022544580A (ja) 骨髄性悪性腫瘍を処置するためのキメラ抗原受容体
Huang et al. Immunotherapy of multiple myeloma
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
US20240327523A1 (en) Depleting monoclonal antibodies against natural killer cells
JP2024540320A5 (cg-RX-API-DMAC10.html)
HK40089985A (en) Tcr-t cell therapy targeting epstein-barr virus
WO2025128002A1 (en) Anti-cd137 antibody and the use thereof
HK1208476B (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same